If enacted, the measure would set rules for pharmacist care and require certain prescribers to offer overdose-drug prescriptions beginning January 1, 2027.
Departments and boards would not be able to charge fees for or approve pharmacist collaborative practice agreements, or set the services covered by them. The rule would apply starting January 1, 2027, if enacted.
Prescribers would have to offer an opioid overdose-drug prescription when an opioid prescription meets any of four risk conditions, including a longer supply or higher dose. This would begin January 1, 2027, if enacted.
Pharmacists could independently provide wellness, prevention, and certain minor-condition services without a collaborative agreement. Limits would exclude several high-risk or specially restricted drugs, and pharmacists would need to refer patients when appropriate.
Pharmacists seeking an Alaska license through reciprocity would also need to meet the state's pain-management and opioid-education requirement and pay required fees. The provision would begin January 1, 2027, if enacted.
The department and professional boards would be barred from charging fees for, approving, defining, or otherwise regulating collaborative practice agreements. The rule would apply to collaborative practice agreements between pharmacists and nonpharmacist practitioners for patient care services. The agreement must use a written protocol approved by a practitioner who is not a pharmacist. The agreement may define the patient care services the pharmacist provides. These provisions would take effect January 1, 2027, if enacted.
Certain licensed prescribers would have to offer an opioid overdose-drug prescription when they prescribe an opioid meeting any listed risk condition. The provisions cover physicians, advanced practice registered nurses, and optometrists who issue opioid prescriptions. An offer would be required for a supply longer than three days, a daily dose of at least 50 morphine milligram equivalents, concurrent benzodiazepine use, or a history of overdose or substance use disorder. The text requires an offer of a prescription, not that the patient accept or receive the drug. These provisions would take effect January 1, 2027, if enacted.
Pharmacists would be allowed to independently provide certain patient care services without a collaborative practice agreement. The services would cover general wellness, disease prevention, and certain minor, self-limiting conditions or services under a statewide standing order. A condition generally could not require a new diagnosis, unless a waived test guides the pharmacist's diagnosis or clinical decision-making. Excluded drugs include many controlled substances, drugs requiring special certified education, and drugs available only through specially authorized pharmacies, with an exception for opioid-use-disorder treatment in a clinic. Pharmacists would have to recognize the limits of their training and refer patients to other practitioners when appropriate. These provisions would take effect January 1, 2027, if enacted.
The pharmacy board would require pharmacist license-transfer applicants to meet the state's pain-management and opioid-education requirement and pay required fees. The rule would apply to pharmacists licensed in another jurisdiction who seek an Alaska license through reciprocity. The other jurisdiction must offer similar licensing for Alaska pharmacists. Applicants would still need to apply, be at least 18, meet Alaska qualifications, have practiced for at least one year, hold an unrestricted license, and pass an Alaska law examination. This provision would take effect January 1, 2027, if enacted.
No hearings or votes scheduled.